2.0 ATA Hyperbaric Chamber: The Clinical Standard Explained

A 2.0 ATA hyperbaric chamber is the standard clinical starting pressure for most UHMS-approved indications. It is also the most commonly used pressure in hyperbaric medicine. A 2024 UHMS survey found that 27.1% of members use 2.0 ATA exclusively, and for radiation cystitis, diabetic foot ulcers, and chronic osteomyelitis, 68 to 75% of clinicians selected 2.0 ATA as their preferred pressure (Laspro et al., 2024).

At 2.0 ATA breathing 100% oxygen, arterial oxygen partial pressure reaches roughly 1,400 mmHg, compared with about 100 mmHg breathing room air. That sits above the pressure where tissue oxygen supports wound healing and antimicrobial activity, far above soft chamber levels (1.3 ATA with air), and at the lower end of the clinical range where the evidence base is deepest.

Hyperbaric pressure tiers, defined

Hyperbaric pressure falls into four practical bands. Knowing which band a study or a chamber sits in is the single most useful thing when comparing options.

What does 2.0 ATA deliver clinically?

2.0 ATA matters clinically because it is the minimum pressure for most UHMS-approved indications, it produces measurably higher tissue oxygen than lower pressures, and it generates fewer adverse events than the higher clinical range of 2.4 to 3.0 ATA. The tissue oxygen data is the clearest evidence.

A study measured transcutaneous oxygen directly in chronic ulcer patients at 1.4 ATA versus 2.0 ATA. Mean TcPO2 was 161 mmHg at 1.4 ATA and 333 mmHg at 2.0 ATA, which is more than double the lower-pressure value (p<0.001). The authors found no evidence that 1.4 ATA benefits chronic ulcer patients (Sack et al., 2024).

Is 2.0 ATA better than 1.5 or 2.4 ATA?

For most standard indications, 2.0 ATA matches higher clinical pressures on outcomes while causing fewer adverse events, which is why it is the default choice. The exceptions run in both directions: emergency conditions call for higher pressures, and mild traumatic brain injury has its strongest evidence at 1.5 ATA.

What conditions is 2.0 ATA used for?

The 2024 UHMS member survey shows which conditions clinicians treat at 2.0 ATA versus higher pressures. The pattern favors 2.0 ATA for wound and bone indications and reserves higher pressures for emergencies.

• Diabetic foot ulcers: 68% of clinicians select 2.0 ATA. The standard protocol is 90-minute sessions, 5 days per week, for 30 to 40 sessions. Multiple randomized trials support wound healing at this pressure.
• Chronic refractory osteomyelitis: 75% of clinicians prefer 2.0 ATA. Courses run longer, typically 40 to 60 sessions, reflecting the time bone tissue needs to respond.
• Radiation cystitis: A direct comparison of 2.0 ATA versus 2.4 ATA found similar good-response rates (72.7% vs 78.3%, p=0.74), with the 2.0 ATA group requiring slightly more sessions (Ajayi et al., 2020).
• Delayed soft tissue radiation injury: Most clinicians use 2.0 to 2.4 ATA. A 2026 study comparing 2.0 and 2.5 ATA for hemorrhagic radiation cystitis found fewer hematuria recurrences at 2.5 ATA but more adverse events, with comparable results on other outcomes (Soriano et al., 2026).
• Carbon monoxide poisoning: This is an exception. Most protocols use 2.4 to 3.0 ATA, based on evidence that higher pressures displace carbon monoxide from hemoglobin faster. 2.0 ATA is generally not used here.

Which chambers operate at 2.0 ATA?

Standard clinical chambers from Perry Baromedical and Sechrist Industries operate across the 2.0 to 3.0 ATA range and remain the reference point for hospital care. For clinics and large home installations seeking 2.0 ATA without full hospital infrastructure, several manufacturers offer chambers rated to that pressure. Prices vary widely by configuration and reseller, so treat these as ranges.

A key distinction is FDA clearance versus CE marking. FDA-cleared chambers have completed the US regulatory process. CE-marked chambers meet European standards but have not been evaluated by the FDA, and a soft shell chamber claiming a continuous 2.0 ATA rating should be checked carefully against its actual achievable pressure and certification before purchase. For personal use in the US both are legally purchasable, but hospital-grade chambers from Perry Baromedical and Sechrist remain the clinical standard. For home options across pressures, see the best hyperbaric chamber for home use guide.

What are the side effects at 2.0 ATA?

A 2024 UHMS survey found the most common adverse events across clinical pressures were temporary myopia (24.4%), ear barotrauma (14.9%), and confinement anxiety (11.5%) (Laspro et al., 2024). These are dose-dependent, meaning they rise with pressure and treatment time, so their rates at 2.0 ATA are lower than at 2.4 ATA and above.

Oxygen toxicity seizures are rare at clinical pressures and cluster at the higher end. Across the literature the reported incidence runs on the order of 1 to 3 per 10,000 treatments, and it is lower at 2.0 ATA than at 2.4 to 3.0 ATA (Hampson and Atik, 2003). For patients weighing 1.5 ATA against 2.0 ATA, the tissue oxygen difference is large (333 mmHg vs 161 mmHg at the closest studied lower pressure), and most clinicians judge the modest increase in adverse event risk to be justified for conditions that respond to HBOT. See the 1.5 ATA and soft chamber guides for the lower-pressure options, and the hard shell vs soft shell comparison for chamber selection.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website